First, there was no selection of patients according to phenotype or endotype, and, as a consequence, many patients with T2high asthma may have been included, a category of patients for whom a beneficial effect of anti-IL-17 treatment would be less expected than for patients with neutrophilic asthma. This evidence concerns the gene IL17A and asthma.